Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for
recurrent or refractory central nervous system tumors for which there are no curative
options. Patients will also be followed for safety, time to progression, event free survival
and overall survival